Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 20/20 | 0.71 |
| ▸ | TLR8 | Q9NR97 | 11/20 | 0.71 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23637775 | 0.89 | TLR7 (0.72) | TLR7TLR8NUDT1 | |
| SCHEMBL5471062 | 0.87 | TLR7 (0.76) | TLR7TLR8NUDT1 | |
| SCHEMBL31126374 | 0.87 | TLR7 (0.76) | TLR7TLR8NUDT1 | |
| SCHEMBL8570489 | 0.87 | TLR7 (0.79) | TLR7TLR8NUDT1 | |
| SCHEMBL4311969 | 0.87 | TLR7 (0.76) | TLR7TLR8NUDT1 | |
| SCHEMBL23304122 | 0.86 | TLR7 (0.65) | TLR7TLR8NUDT1 | |
| SCHEMBL29639783 | 0.86 | TLR7 (0.65) | TLR7TLR8NUDT1 | |
| SCHEMBL1490576 | 0.86 | TLR7 (0.74) | TLR7TLR8NUDT1 | |
| SCHEMBL24809666 | 0.85 | TLR7 (0.80) | TLR7TLR8NUDT1 | |
| SCHEMBL22512634 | 0.85 | TLR7 (0.87) | TLR7TLR8NUDT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4306523-A2 | IMIDAZOQUINOLINE COMPOUNDS AND USES THEREOF | Birdie Biopharmaceuticals, Inc. (KY) | 2024-01-17 | — | — | EP | disclosed |
| US-20230310469-A1 | METHODS OF TREATING SYMPTOMS OF CORONAVIRUS INFECTION WITH TOLL-LIKE-RECEPTOR AGONISTS | Accencio LLC | 2023-10-05 | — | — | US | disclosed |
| US-20230310469-A1 | METHODS OF TREATING SYMPTOMS OF CORONAVIRUS INFECTION WITH TOLL-LIKE-RECEPTOR AGONISTS | Accencio LLC | 2023-10-05 | — | — | US | disclosed |
| EP-3846807-B1 | IMIDAZOQUINOLINE COMPOUNDS AND USES THEREOF | BIRDIE BIOPHARMACEUTICALS INC (KY) | 2023-08-02 | — | — | EP | disclosed |
| US-20210214354-A1 | IMIDAZOQUINOLINE COMPOUNDS AND USES THEREOF | BIRDIE BIOPHARMACEUTICALS, INC. (KY) | 2021-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210214354-A1 | IMIDAZOQUINOLINE COMPOUNDS AND USES THEREOF | TLR7, TLR8, TLR3 | TLR7 1/4885TLR8 2/4885NUDT1 515/4885 |
| US-20230310469-A1 | METHODS OF TREATING SYMPTOMS OF CORONAVIRUS INFECTION WITH TOLL-LIKE-RECEPTOR AGONISTS | TLR3, TLR7, TLR8 | TLR7 2/4885TLR8 3/4885NUDT1 2544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.